Disruptive Gene Editing
Harnessing gene editing to treat rare diseases such as Epidermolysis Bullosa (EB)

The Challenge
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic skin fragility and blistering disorder in which no curative treatment currently exists with palliative care only in use.
The Solution
Our proposed solution is to develop a gene editing curative treatment that can be applied topically to wound sites of RDEB patients.
This therapeutic approach will enable the permanent correction of the underlying mutations that give rise to RDEB, in a non-invasive manner.
The Team
- Team Lead: Professor Wenxin Wang, Charles Institute of Dermatology, School of Medicine, University College Dublin
- Team Co-Lead: Dr Nan Zhang, School of Mechanical and Materials Engineering, University College Dublin
Project Team:
- Dr Irene Lara-Sáez, Charles Institute of Dermatology, School of Medicine, University College Dublin
- Mr Jonathan O’Keeffe Ahern, Charles Institute of Dermatology, School of Medicine, University College Dublin
Societal Impact Champion
- Dr Sinead Hickey, Head of Research of DEBRA Ireland